

ABCCEDP ELIGIBILITY GUIDELINES—EFFECTIVE JANUARY 15, 2024

ABCCEDP Eligibility Criteria

- ❖ Be a resident of Alabama (have an Alabama address)
- ❖ Women with a household income at or below 250% of the Federal Poverty Level
- ❖ Women who have no insurance
- ❖ Women who meet the age and other eligibility requirements as described below

Breast Cancer Screening

- ❖ **Women age 50-64: every year**
CBE and Screening Mammogram
- ❖ **Women age 40-49: every other year**
CBE and Screening Mammogram
- ❖ **Women age 40-64 (High-Risk): every year**
Women in this category may be eligible for a CBE, Screening Mammogram, Diagnostic Mammogram, Ultrasound, MRI, Biopsy, or other Diagnostics. If MRI is indicated complete MRI prior-approval form which outlines MRI eligibility criteria.
 - ◆ Breast Mass
 - ◆ Bloody nipple discharge expressed by Provider during CBE
 - ◆ Dimpling noted by Provider during CBE
 - ◆ Personal history of breast cancer (***Must have documentation of breast cancer***)
 - ◆ Genetic Mutation such as BRCA 1 or 2 (***Must have documentation of genetic mutation***)
 - ◆ 1st degree relative with breast cancer (mother, sister, father)
 - ◆ Greater than 20% lifetime risk of breast cancer based on risk assessment models largely dependent of family history
 - ◆ History of radiation treatment to the chest area before age of 30 (***typically for Hodgkin's Lymphoma***)
- ❖ **Women age 65 or older with no insurance or Medicare Part A only: every year**
CBE and Screening Mammogram

Cervical Cancer Screening

Screening Guidelines:

- ❖ **Women (Average Risk) age 40-64 (for those NOT eligible for Family Planning)***
Ages 40-64: Co-test every 5 years, Pap smear every 3 years
- ❖ **Women (Average Risk) age 21-39 (who have had tubal ligation or partial hysterectomy with cervix remaining)**
 - ◆ Ages 21-39: Pap test only every 3 years
 - ◆ Ages 30-39: Co-test every 5 years or Pap test every 3 years
- ❖ **Women (High Risk) any age with a past personal history (biopsy) of CIN II, CIN III, or invasive cervical cancer**
Follow ASCCP recommended guidance for surveillance after treatment and follow-up, thereafter for at least 20 years post treatment (for those NOT eligible for Family Planning)*
- ❖ **Women (High Risk) ages 21-64 (for those NOT eligible for Family Planning)* with one of the following:**
 - ◆ Diethylstilbestrol (DES) exposure in utero
 - ◆ Immuno-compromised due to health condition
 - ◆ Organ transplantation
 - ◆ Human Immunodeficiency Virus (HIV)
 - Ages 21-29: Annual Pap test (for those NOT eligible for Family Planning)*
 - Ages 30-64: Co-test every 3 years or annual Pap test (for those NOT eligible for Family Planning)*
- ❖ **Women age 65 or older with no insurance or Medicare Part A only** if meets ASCCP guidelines for screening

Diagnostic Follow-Up Guidelines:

- ❖ **Women (High Risk) age 21-39 who need diagnostic follow-up for abnormal cervical cancer screening results**
Follow ASCCP guidelines regarding appropriate cervical cancer diagnostics and follow-up

***Women of any age who have had a bilateral tubal ligation or partial hysterectomy are not eligible for Family Planning.**